Industry
Biotechnology
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
July 18, 2024 | 1:05 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 1:13 pm
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 3:46 pm
Portfolio Pulse from Benzinga Insights
May 10, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
April 24, 2024 | 1:17 pm
Portfolio Pulse from Benzinga Insights
April 10, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
April 09, 2024 | 1:18 pm
Portfolio Pulse from Benzinga Newsdesk
April 04, 2024 | 11:50 pm
Portfolio Pulse from Henry Khederian
April 04, 2024 | 3:49 pm
Portfolio Pulse from Benzinga Newsdesk
April 03, 2024 | 3:07 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.